

## Disclosures

### Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Medtronic Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Arrhythmias and Clinical EP Heart Failure and Cardiomyopathies</a>
spectranetics	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Arrhythmias and Clinical EP</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (12)

Trial Name	Trial Sponsor	Trial Funding Source
Genetic-AF	ARCA biopharma, Inc.	ARCA biopharma, Inc.
S-ICD Registry	Boston Scientific	Boston Scientific
Micra Leadless Pacemaker	MEDTRONIC	MEDTRONIC
CABANA	NHLBI	NHLBI
Star VT	St Jude	St Jude
Cross-X4	St Jude Medical	St Jude
ICD/LVAD	Thoratec	Thoratec
VA FAR AF Trial	Vanderbilt	Vanderbilt
QTPS, study of QT prolonging drugs in the hospital	Vanderbilt	Vanderbilt
VT Ablation Resistry	Vanderbilt	Vanderbilt
Prospective Trial of TYRX Pouch	Vanderbilt/Medtronic	Vanderbilt/Medtronic
Giraffe	Zio Patch	Zio Patch

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (7)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2015	Pneumothorax during Pacemaker	Defendant	Right sided pneumothorax during left sided pacemaker	Modest (< \$5,000)
2013	EP Procedure Complication	Defendant	Perforation during EP Procedure	None (\$0)
2012	Pacemaker Complication	Defendant	Pacemaker placed into left ventricle	None (\$0)
2012	Pacemaker Product Liability	Defendant	The plaintiff claims that the pacemaker was defective and causes heart failure	None (\$0)
2010	Complications of Ablation	Defendant	Testified that a perforation is an expected complication of an ablation.	None (\$0)
2010	Perioperative Atrial Fibrillation	Defendant	SUpported the Standard of Care approach of the cardiologist	None (\$0)
2008	Long QT	Defendant	Testified that the patient had long QT as the cause of a cardiac arrest rather than surgical maleficence.	None (\$0)

† Commercial Funding Source | ‡ Trial Name

**Certified Education Attestation** | Signed on 1/23/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 1/23/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 1/23/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 1/23/2024

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.